source
- Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drugWerewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and raised $150 million, positioning the biotech to take…Fierce Biotech · 8h ago↗ source
- Regeneron secures FDA approval for Pasatru, second U.S. treatment for rare bone disease FOPRegeneron received FDA approval for its antibody garetosmab, marketed as Pasatru, for treatment of fibrodysplasia ossificans progressiva (FOP) in adults. The approval makes Pasatru the second ther…